160 related articles for article (PubMed ID: 9255346)
1. [Pharmacological control of biosynthesis pathway of mevalonate: effect on the proliferation of arterial smooth muscle cells].
Corsini A; Arnaboldi L; Quarato P; Ferri N; Granata A; Fumagalli R; Paoletti R
C R Seances Soc Biol Fil; 1997; 191(2):169-94. PubMed ID: 9255346
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological control of the mevalonate pathway: effect on arterial smooth muscle cell proliferation.
Raiteri M; Arnaboldi L; McGeady P; Gelb MH; Verri D; Tagliabue C; Quarato P; Ferraboschi P; Santaniello E; Paoletti R; Fumagalli R; Corsini A
J Pharmacol Exp Ther; 1997 Jun; 281(3):1144-53. PubMed ID: 9190847
[TBL] [Abstract][Full Text] [Related]
3. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase.
Corsini A; Mazzotti M; Raiteri M; Soma MR; Gabbiani G; Fumagalli R; Paoletti R
Atherosclerosis; 1993 Jun; 101(1):117-25. PubMed ID: 8216498
[TBL] [Abstract][Full Text] [Related]
4. Ajoene, a garlic compound, inhibits protein prenylation and arterial smooth muscle cell proliferation.
Ferri N; Yokoyama K; Sadilek M; Paoletti R; Apitz-Castro R; Gelb MH; Corsini A
Br J Pharmacol; 2003 Mar; 138(5):811-8. PubMed ID: 12642382
[TBL] [Abstract][Full Text] [Related]
5. Mevalonic acid-dependent degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase in vivo and in vitro.
Correll CC; Edwards PA
J Biol Chem; 1994 Jan; 269(1):633-8. PubMed ID: 8276863
[TBL] [Abstract][Full Text] [Related]
6. Simvastatin modulates the heat shock response and cytotoxicity mediated by oxidized LDL in cultured human endothelial smooth muscle cells.
Pirillo A; Jacoviello C; Longoni C; Radaelli A; Catapano AL
Biochem Biophys Res Commun; 1997 Feb; 231(2):437-41. PubMed ID: 9070296
[TBL] [Abstract][Full Text] [Related]
7. Farnesol is not the nonsterol regulator mediating degradation of HMG-CoA reductase in rat liver.
Keller RK; Zhao Z; Chambers C; Ness GC
Arch Biochem Biophys; 1996 Apr; 328(2):324-30. PubMed ID: 8645011
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro.
Flint OP; Masters BA; Gregg RE; Durham SK
Toxicol Appl Pharmacol; 1997 Jul; 145(1):91-8. PubMed ID: 9221828
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of squalene synthase but not squalene cyclase prevents mevalonate-mediated suppression of 3-hydroxy-3-methylglutaryl coenzyme A reductase synthesis at a posttranscriptional level.
Peffley DM; Gayen AK
Arch Biochem Biophys; 1997 Jan; 337(2):251-60. PubMed ID: 9016820
[TBL] [Abstract][Full Text] [Related]
10. Selective inhibition of cholesterol biosynthesis in brain cells by squalestatin 1.
Crick DC; Suders J; Kluthe CM; Andres DA; Waechter CJ
J Neurochem; 1995 Sep; 65(3):1365-73. PubMed ID: 7643114
[TBL] [Abstract][Full Text] [Related]
11. Effect of the new HMG-CoA reductase inhibitor cerivastatin (BAY W 6228)on migration, proliferation and cholesterol synthesis in arterial myocytes.
Corsini A; Arnaboldi L; Raiteri M; Quarato P; Faggiotto A; Paoletti R; Fumagalli R
Pharmacol Res; 1996 Jan; 33(1):55-61. PubMed ID: 8817647
[TBL] [Abstract][Full Text] [Related]
12. Effect of squalene synthase inhibition on the expression of hepatic cholesterol biosynthetic enzymes, LDL receptor, and cholesterol 7 alpha hydroxylase.
Ness GC; Zhao Z; Keller RK
Arch Biochem Biophys; 1994 Jun; 311(2):277-85. PubMed ID: 7911291
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the isoprenoid biosynthesis pathway; detection of intermediates by UPLC-MS/MS.
Henneman L; van Cruchten AG; Kulik W; Waterham HR
Biochim Biophys Acta; 2011 Apr; 1811(4):227-33. PubMed ID: 21237288
[TBL] [Abstract][Full Text] [Related]
14. Regulation of cholesterol 7 alpha-hydroxylase expression by sterols in primary rat hepatocyte cultures.
Doerner KC; Gurley EC; Vlahcevic ZR; Hylemon PB
J Lipid Res; 1995 Jun; 36(6):1168-77. PubMed ID: 7665995
[TBL] [Abstract][Full Text] [Related]
15. Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Corsini A; Bernini F; Quarato P; Donetti E; Bellosta S; Fumagalli R; Paoletti R; Soma VM
Cardiology; 1996; 87(6):458-68. PubMed ID: 8904671
[TBL] [Abstract][Full Text] [Related]
16. Proliferative effect of mevalonate metabolites other than isoprenoids on cultured vascular smooth muscle cells.
Sawamura M; Li N; Nara Y; Yamori Y
Clin Exp Pharmacol Physiol; 1993; 20(7-8):509-14. PubMed ID: 8403532
[TBL] [Abstract][Full Text] [Related]
17. RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase.
Amin D; Rutledge RZ; Needle SN; Galczenski HF; Neuenschwander K; Scotese AC; Maguire MP; Bush RC; Hele DJ; Bilder GE; Perrone MH
J Pharmacol Exp Ther; 1997 May; 281(2):746-52. PubMed ID: 9152381
[TBL] [Abstract][Full Text] [Related]
18. Metabolism of farnesyl diphosphate in tobacco BY-2 cells treated with squalestatin.
Hartmann MA; Wentzinger L; Hemmerlin A; Bach TJ
Biochem Soc Trans; 2000 Dec; 28(6):794-6. PubMed ID: 11171211
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of cholesterol production but not of nonsterol isoprenoid products induces neuronal cell death.
Michikawa M; Yanagisawa K
J Neurochem; 1999 Jun; 72(6):2278-85. PubMed ID: 10349836
[TBL] [Abstract][Full Text] [Related]
20. Massive production of farnesol-derived dicarboxylic acids in mice treated with the squalene synthase inhibitor zaragozic acid A.
Vaidya S; Bostedor R; Kurtz MM; Bergstrom JD; Bansal VS
Arch Biochem Biophys; 1998 Jul; 355(1):84-92. PubMed ID: 9647670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
